

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
Scrip Symbol: SPARC

BSE Limited

Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code: 532872

Dear Sir/ Madam,

Sub: Outcome of the meeting of the Securities Allotment Committee held today i.e. on May 19, 2026, in terms of Regulation 30 read with Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and approval of the Board of Directors of Sun Pharma Advanced Research Company Limited (“**Company**”) at its meeting held on January 14, 2026, and approval of the members of the Company at their Extra-Ordinary General Meeting held on February 09, 2026 and pursuant to In-principle approvals granted by BSE Limited and National Stock Exchange of India Limited vide their respective letters dated May 08, 2026, the Securities Allotment Committee of the Company, has approved and allotted 3,85,10,000 (Three Crores Eighty Five Lakh Ten Thousand) warrants (“**Warrants**”) to Shanghvi Finance Private Limited (“**Allottee**”) at an issue price of INR 155.80/- (Indian Rupees One Hundred and Fifty Five and Eighty paise only) per Warrant (“**Warrant Issue Price**”) on preferential basis, out of which the Company has received an amount of INR 1,49,99,64,500/- (India Rupees One Hundred Forty Nine Crores Ninety Nine Lakhs Sixty Four Thousand Five Hundred only) which is equivalent to 25% of the Warrant Issue Price, in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“**SEBI ICDR Regulations**”).

Each of the Warrant, so allotted, is convertible into or exchangeable for one fully paid-up equity share of face value of INR. 1/- (Indian Rupee One) of the Company in accordance with the provisions of SEBI ICDR Regulations.



There is no change in the paid-up equity share capital of the Company, on allotment of convertible Warrants, however, the equity share capital will be enhanced upon conversion of Warrants.

The meeting of the Committee commenced at 12:00 PM (IST) and concluded at 12:15 PM (IST).

We request you to take the aforesaid information on your records.

For **Sun Pharma Advanced Research Company Limited**

Kajal Damania
Company Secretary and Compliance Officer